VistaGen Therapeutics is a late clinical-stage biopharmaceutical company developing non-systemic intranasal pherine product candidates that activate nose-to-brain neurocircuits without systemic absorption. Its pipeline includes five clinical-stage candidates: fasedienol (Phase 3, social anxiety disorder), itruvone (Phase 2A, major depressive disorder), PH80 (Phase 2A, vasomotor symptoms and premenstrual dysphoric disorder), PH15 (Phase 2A, mental fatigue), and PH284 (Phase 2A, cancer cachexia). Fasedienol is the lead candidate in the registration-directed PALISADE Program.
Q2 FY2026 — expected 2026-09-10
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-06-17 | 2025-03-31 | 0001411685-25-000041 | EDGAR | 86K words |
| 2024-06-11 | 2024-03-31 | 0001411685-24-000022 | EDGAR | — |
| 2023-06-28 | 2023-03-31 | 0001437749-23-018793 | EDGAR | — |
| 2022-06-23 | 2022-03-31 | 0001851734-22-000349 | EDGAR | — |
| 2021-06-29 | 2021-03-31 | 0001654954-21-007380 | EDGAR | — |
| 2020-06-29 | 2020-03-31 | 0001654954-20-007107 | EDGAR | — |
| 2019-06-25 | 2019-03-31 | 0001654954-19-007632 | EDGAR | — |
| 2018-06-26 | 2018-03-31 | 0001654954-18-006990 | EDGAR | — |
| 2017-06-29 | 2017-03-31 | 0001654954-17-005976 | EDGAR | — |
| 2016-06-24 | 2016-03-31 | 0001415889-16-006331 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-12 | 2025-12-31 | 0001628280-26-007718 | EDGAR | 60K words |
| 2025-11-13 | 2025-09-30 | 0001628280-25-052079 | EDGAR | — |
| 2025-08-07 | 2025-06-30 | 0001411685-25-000064 | EDGAR | — |
| 2025-02-13 | 2024-12-31 | 0001411685-25-000019 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0001411685-24-000048 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001411685-24-000037 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0001437749-24-003916 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001437749-23-031293 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0001437749-23-023127 | EDGAR | — |
| 2023-02-07 | 2022-12-31 | 0001851734-23-000035 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001851734-22-000662 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001851734-22-000432 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001628280-26-054341 | EDGAR | — |
| 2026-08-05 | 0001628280-26-053304 | EDGAR | — |
| 2026-07-31 | 0001628280-26-051251 | EDGAR | — |
| 2026-04-02 | 0001628280-26-023176 | EDGAR | 1K words |
| 2026-03-18 | 0001628280-26-019455 | EDGAR | — |
| 2026-03-16 | 0001628280-26-018163 | EDGAR | — |
| 2026-03-11 | 0001628280-26-016652 | EDGAR | — |
| 2026-02-20 | 0001628280-26-010035 | EDGAR | — |
| 2026-02-12 | 0001628280-26-007715 | EDGAR | — |
| 2026-02-06 | 0001628280-26-006078 | EDGAR | — |
389 total filings indexed. 357 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001411685 |
| Ticker | VTGN |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.vistagen.com |
| Listed | 2009-07-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/VTGN (~200 tokens, structured JSON with cryptographic provenance)